Francis Crick, UCL and AZ identify why treatment fails for NSCLC patients
NSCLC accounts for around 85% of all lung cancer cases, particularly in non-smoking patients
Read More
Tag: osimertinib
NICE backing for AZ’ Tagrisso
The Institute has endorsed the drug for first-line treatment of adults with locally-advanced or EGFR mutation-positive NSCLC
Read More
Tagrisso shows ‘unprecedented’ disease free survival in lung cancer
The Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent the the risk of disease recurrence or death by around 80%
Read More
AZ’ Tagrisso improves overall survival in lung cancer
The trial previously met its primary endpoint in July 2017, showing a statistically-significant and clinically-meaningful improvement in progression-free survival.
Read More
EU approves first-line use of AZ’ Tagrisso in lung cancer
AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
Read More
AZ’ lung cancer drug Tagrisso backed for first-line use
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
Read More
US widens use of AZ’ Tagrisso in lung cancer
AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.
Read More
AZ’ Tagrisso offers sustained benefit in lung cancer
AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.
Read More
EU regulators review AZ’ Tagrisso for first-line use in lung cancer
European regulators are reviewing AstraZeneca’s application to market Tagrisso for the first-line treatment of adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have EGFR mutations.
Read More
AZ teams up with G1 on lung cancer combo
AstraZeneca has signed a deal with US group G1 Therapeutics to test the potential of a new combination therapy for lung cancer.
Read More
AZ’ lung cancer drug Tagrisso bags breakthrough status
AstraZeneca’s Tagrisso has been awarded breakthrough status in the US as a first-line treatment for a specific type of non-small cell lung cancer (NSCLC), potentially speeding up its development and regulatory pathway.
Read More
Tagrisso shows benefit in NSCLC patients with CNS metastases
AstraZeneca has presented new data showing that Tagrisso also extends progression-free survival for non-small cell lung cancer (NSCLC) patients who have central nervous system (CNS) metastases.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
